Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.8% - Still a Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) traded up 6.8% during mid-day trading on Tuesday . The stock traded as high as $13.27 and last traded at $13.23. 1,196,055 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 1,823,440 shares. The stock had previously closed at $12.38.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of research analyst reports. Roth Capital reissued a "buy" rating and set a $31.00 price objective on shares of Capricor Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Friday. Finally, Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $35.50.

Capricor Therapeutics Trading Up 1.1%

The stock's fifty day moving average price is $10.80 and its 200-day moving average price is $12.64. The firm has a market cap of $571.65 million, a price-to-earnings ratio of -11.76 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same period in the previous year, the firm earned ($0.31) EPS. Analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after acquiring an additional 37,868 shares in the last quarter. Swiss National Bank purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $930,000. Alliancebernstein L.P. purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $183,000. Nuveen Asset Management LLC raised its holdings in Capricor Therapeutics by 392.7% during the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after purchasing an additional 134,791 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 2,361 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.